For Immediate Release
Chicago, IL – January 14, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: UnitedHealth Group (UNH - Free Report) , CVS Health (CVS - Free Report) , Morgan Stanley (MS - Free Report) , Charles Schwab (SCHW - Free Report) and Uber Technologies (UBER - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Research Reports for UnitedHealth, CVS and Morgan Stanley
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group, CVS Health and Morgan Stanley. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
UnitedHealth’s shares have underperformed the Zacks Medical Insurance industry over the past year (+19% vs. +19.3%). The Zacks analyst believes that UnitedHealth Group stands apart in the industry by virtue of healthcare services, technology and innovations offered by its unit, Optum.
Numerous acquisitions made by the company have led to inorganic growth. Its solid balance sheet and consistent cash flow generation enable investment in business. Also, capital management by dividend payout and share buyback is another positive. Strong earnings guidance by the company instills investors' confidence.
The stock has seen the Zacks Consensus Estimate for current-year earnings being revised 0.8% upward over the last 60 days. The slowdown of growth in international operations and underperformance in Medicaid business are some concerns.
Shares of CVS have gained +14.5% in the past three months against the Zacks Retail Pharmacies and Drug Stores industry's rise of +10.1%. The Zacks analyst is pleased with its solid progress in terms of the 2020 selling season. The company has started to witness increased customer traffic and incremental sales in pharmacy front store and MinuteClinics.
The company successfully executed its strategic priorities, resulting in all three of the company’s segments performing in line with, or above its expectations. The Health Care Benefits segment, launched after the Aetna acquisition, is showing strong momentum. The company posted better-than-expected third-quarter results on the back of robust progresses.
However, persistent reimbursement pressure and the impact of recent generic introductions dented the company’s retail LTC business growth. Also, Omnicare business performance should continue to remain soft through the rest of 2019.
Morgan Stanley's shares have gained +17.5% over the past six months against the Zacks Investment Banking industry's rise of +11.4%. The Zacks analyst believes that steady loan growth, strong balance sheet position and the company's continued focus on its corporate lending business are expected to continue to aid profitability.
The company has an impressive earnings surprise history. Its earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters. Notably, the acquisition of Solium Capital is in sync with the company’s efforts to further strengthen its wealth management business.
However, weaknesses in investment banking and trading are expected to hinder fee income growth to some extent and hurt the company’s top line. Moreover, given the decline in interest rates and a tough operating backdrop, the company’s performance is expected to remain sluggish in the near term.
Other noteworthy reports we are featuring today include Charles Schwab and Uber Technologies.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.